Literature DB >> 16504545

Are there potential problems with generic substitution of antiepileptic drugs? A review of issues.

P Crawford1, M Feely, A Guberman, G Kramer.   

Abstract

In response to increasing cost pressures, healthcare systems are encouraging the use of generic medicines. This review explores potential problems with generic substitution of antiepileptic drugs (AEDs). A broad search strategy identified approximately 70 relevant articles. Potential problems with generic substitution included: The limited evidence (mainly case reports with some pharmacokinetic studies) appears to support these concerns for older AEDs. As a result, restrictions on use of specific generic AEDs are in place in some countries and recommended by some lay epilepsy organisations. As more AEDs lose patent protection, it is important to examine the question of whether generic substitution may pose problems for patients with epilepsy, and whether there should be safeguards to ensure that both physician and patient are informed when generic substitution occurs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16504545     DOI: 10.1016/j.seizure.2005.12.010

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  32 in total

1.  Generic Substitution Issues: Brand-generic Substitution, Generic-generic Substitution, and Generic Substitution of Narrow Therapeutic Index (NTI)/Critical Dose Drugs.

Authors:  Marian Sorin Paveliu; Simona Bengea; Fraga Silvia Paveliu
Journal:  Maedica (Buchar)       Date:  2011-01

Review 2.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

3.  Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.

Authors:  Richard A Hansen; Jingjing Qian; Richard Berg; James Linneman; Enrique Seoane-Vazquez; Sarah K Dutcher; Saeid Raofi; C David Page; Peggy Peissig
Journal:  Pharmacotherapy       Date:  2017-03-20       Impact factor: 4.705

4.  Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.

Authors:  Mario Del Tacca; Giuseppe Pasqualetti; Antonello Di Paolo; Agostino Virdis; Gabriele Massimetti; Giovanni Gori; Daniele Versari; Stefano Taddei; Corrado Blandizzi
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

5.  Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin.

Authors:  Marc Maliepaard; Nikola Banishki; Christine C Gispen-de Wied; Steven Teerenstra; André J Elferink
Journal:  Eur J Clin Pharmacol       Date:  2011-04-15       Impact factor: 2.953

6.  Exploring community pharmacists' views on generic medicines: a nationwide study from Malaysia.

Authors:  Chee Ping Chong; Mohamed Azmi Hassali; Mohd Baidi Bahari; Asrul Akmal Shafie
Journal:  Int J Clin Pharm       Date:  2011-01-13

Review 7.  Bioequivalence of antiepileptic drugs: how close is close enough?

Authors:  Barry E Gidal
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

8.  alpha(2)delta Modulators for Management of Compression Neuropathic Pain: A Review of Three Case Series.

Authors:  Tariq A Tramboo; Showket Gurkhoo
Journal:  Indian J Palliat Care       Date:  2009-07

9.  Substitution of anticonvulsant drugs.

Authors:  Bernhard J Steinhoff; Uwe Runge; Otto W Witte; Hermann Stefan; Andreas Hufnagel; Thomas Mayer; Günter Krämer
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

Review 10.  Requirements for generic anti-epileptic medicines: a regulatory perspective.

Authors:  Marc Maliepaard; Yechiel A Hekster; Arnoud Kappelle; Eugène P van Puijenbroek; André J Elferink; Jan Welink; Christine C Gispen-de Wied; Frits J F Lekkerkerker
Journal:  J Neurol       Date:  2009-07-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.